zur Navigation zum Inhalt

Practice-changing refinements of lung cancer staging

01/2017 The 8th edition of the TNM classification has recently come into effect. Compared to the 7th edition published in 2009 [1], several important adjustments have been made to lung cancer staging with the aim of improving prognostication and research [2]. [...]

Liquid biopsy in the context of EGFR and other mutations

01/2017 Compared to tissue biopsy and re-biopsy, liquid biopsy offers several advantages, including minimal-invasiveness, the opportunity for serial measurements over time to monitor tumour response, and detection of resistance mutations in the plasma prior to radiographic detection [1]. [...]

Who is a candidate for immunotherapy?

01/2017 WHICH MARKERS ARE AVAILABLE THAT DEFINE PATIENTS WHO ARE SUITABLE FOR IMMUNOTHERAPY? When we look at immunotherapy for NSCLC, we should realize that approximately 20 % of treated patients show a response. To direct treatment to patients with a higher likelihood of response, biomarkers might be of value. [...]

Immunotherapy: novel anti-PD-L1 antibodies & various combination regimens

01/2017 OAK subgroup analyses

As compared to anti-PD-1 antibodies, the advantage of antibodies directed against PD-L1 is that they can inhibit PD-1/ PD-L1 interactions while leaving the PD-1/ PD-L2 pathway intact, thus potentially preserving peripheral immune homoeostasis. [...]

Anti-angiogenesis with nintedanib: activity in mesothelioma, and potential biomarkers

01/2017 LUME-Meso

Malignant pleural mesothelioma generally has poor patient prognosis, as it is often diagnosed at an advanced stage. The only approved regimen consists of the combination of pemetrexed and cisplatin, which gives rise to a median OS of approximately 1 year [1]. [...]

Dieser Artikel ist nur für registrierte Mitglieder zugänglich Ixekizumab bei Plaque-Psoriasis: Aufnahme in die dunkelgelbe Box

01/2017 Taltz® ab sofort erstattungsfähig: Neuer Interleukin-17A-Inhibitor ermöglicht hohes Maß an Erscheinungsfreiheit

Der neue IL-17A-Inhibitor Ixekizumab (Handelsname Taltz®) ist seit dem 01. Januar 2017 in der dunkelgelben Box des Erstattungskodex (EKO) enthalten und damit ab sofort erstattungsfähig. [...]

Medizin heute

Aktuelle Printausgaben